Frank Torti - Jul 29, 2025 Form 3 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
President and Vant Chair
Signature
/s/ Jo Chen, as Attorney-in-Fact for Frank Torti
Stock symbol
ROIV
Transactions as of
Jul 29, 2025
Transactions value $
$0
Form type
3
Date filed
7/29/2025, 09:00 PM
Previous filing
Apr 3, 2025
Next filing
Aug 1, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Torti Frank President and Vant Chair C/O ROIVANT SCIENCES LTD., 7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM /s/ Jo Chen, as Attorney-in-Fact for Frank Torti 2025-07-29 0001647805

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ROIV Stock Option (Right to Buy) Jul 29, 2025 Common Shares 1.61M $11.03 Direct F1
holding ROIV Stock Option (Right to Buy) Jul 29, 2025 Common Shares 585K $11.50 Direct F1
holding ROIV Stock Option (Right to Buy) Jul 29, 2025 Common Shares 146K $10.08 Direct F1
holding ROIV Stock Option (Right to Buy) Jul 29, 2025 Common Shares 219K $13.07 Direct F1
holding ROIV Stock Option (Right to Buy) Jul 29, 2025 Common Shares 563K $10.00 Direct F1
holding ROIV Stock Option (Right to Buy) Jul 29, 2025 Common Shares 1.13M $10.00 Direct F1
holding ROIV Stock Option (Right to Buy) Jul 29, 2025 Common Shares 6.03M $3.85 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an award of stock options to purchase Common Shares that is fully vested.
F2 Reflects an award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date (except as otherwise provided in the award documentation).

Remarks:

Exhibit 24 - Power of Attorney